BIODTECH, INC.

BIRMINGHAM, AL · CIK 0001316122 · Medtech · Private

An assay measuring endotoxin neutralization in human plasma as a biomarker of immune activation and disease severity

Grants
$979K
2 awards
Sector median: 1
Raised
$575K
1 Form D · Aug 2010
194 months since last filing
Contracts
—
No federal contracts on record
Patents
6
0 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$575,000
Federal grantDepartment of Health and Human Services · Phase II · Endotoxin Neutralization as a Biomonitor for HIV Disease Progression$501,326
Federal grantDepartment of Health and Human Services · Phase II · Endotoxin Neutralization as a Biomonitor for HIV Disease Progression$477,786
Federal grant · SBIR/STTRForm D · SEC

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
919Granite Medical, LLC——
920LungLife AI, Inc.—$53M
921BIOCHIP LABS, INC.——
922BIODTECH, INC.—$575K
923Innova Vascular, Inc.—$22M
924AGITATED SOLUTIONS, LLC—$515K
925Qardio, Inc.—$39M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Alan DeanDirector
  • Michael PepeDirector · Executive Officer
  • Ira WeissDirector · Executive Officer

Patents

USPTO · 0 granted of 6
  • The Use Of Endotoxin Neutralization As A Biomarker For Intestinal Wall Damageapplication
  • The Use Of Endotoxin Neutralization As A Biomarker For Sepsisapplication
  • The Use Of Endotoxin Neutralization As A Biomarker For Intestinal Wall Damageapplication
  • Enhancing Endotoxin Detectionapplication
  • Enhancing Endotoxin Detectionapplication
  • Enhancing Endotoxin Detectionapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.